Epithelial Splicing Regulatory Protein (ESPR1) Expression in an Unfavorable Prognostic Factor in Prostate Cancer Patients

• Published in: Frontiers in oncology Vol. 10; p. 556650
• Main Authors: Lee, Hyung Ho, Lee, Andy Jinseok, Park, Weon Seo, Lee, Jongkeun, Park, Jongkeun, Park, Boram, Joung, Jae Young, Lee, Kang Hyun, Hong, Dongwan, Kim, Sung Han
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 26.10.2020
• Subjects: biochemical recurrence (BCR); clinical validation; ESRP1 gene; Oncology; prostate cancer; prostate cancer-specific mortality; survival analysis; prostate cancer; biochemical recurrence (BCR); survival analysis; prostate cancer-specific mortality; clinical validation; ESRP1 gene
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.556650

To evaluate the role of epithelial splicing regulatory protein 1 (ESRP1) expression in survival prognoses and disease progression for prostate cancer (PC) using The Cancer Genome Atlas (TCGA) dataset and to validate it using patients' prostatectomy specimens. A preliminary investigation into the clinical significance of ESRP1 in PC was conducted using TCGA PC PRAD dataset and then using immunohistochemistry in 514 PC patients' tissue microarrays of radical prostatectomy specimens. The interpretation of immunohistochemistry was done using its intensity (high vs. low) or the semi-quantitative expression value (H-score, 0-300). The prognostic significance of ESRP1 expression was analyzed for biochemical recurrence (BCR), recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) using the Cox proportional-hazards model (p < 0.05). In the publicly available prostate adenocarcinoma dataset, ESRP1 expression was significantly higher in the tumor samples compared to the normal samples (p < 0.001). Survival analysis showed that the tumor samples in the ESRP1-high group had significantly worse BCR-free survival and RFS compared to the ESRP1-low group (p < 0.05), whereas OS was not (p=0.08). These results were largely consistent with the 514 patients' clinical data during a median 91.2 months of follow-up. After adjusting for significant prognostic clinicopathological factors, the multivariable models showed that the ESRP1 was a significantly risk factor for CSS (Hazard ratio 3.37, p = 0.034) and for BCR (HR 1.34, p=0.049) without any significance for OS (p=0.464). The higher ESRP1 expression appeared increased risk of disease progression and cancer-specific death in PC.